Fintel reports that on August 7, 2024, DNB MARKETS upgraded their outlook for Novo Nordisk A (NYSE:NVO) from Hold to Buy.
Analyst Price Forecast Suggests 7.70% Upside
As of August 6, 2024, the average one-year price target for Novo Nordisk A is $143.75/share. The forecasts range from a low of $82.76 to a high of $184.37. The average price target represents an increase of 7.70% from its latest reported closing price of $133.47 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Novo Nordisk A is 226,110MM, a decrease of 12.36%. The projected annual non-GAAP EPS is 35.31.
What is the Fund Sentiment?
There are 2,110 funds or institutions reporting positions in Novo Nordisk A. This is an increase of 177 owner(s) or 9.16% in the last quarter. Average portfolio weight of all funds dedicated to NVO is 0.62%, an increase of 7.33%. Total shares owned by institutions increased in the last three months by 3.94% to 369,371K shares. 
The put/call ratio of NVO is 0.78, indicating a bullish outlook.
What are Other Shareholders Doing?
Jennison Associates holds 21,221K shares representing 0.48% ownership of the company. In its prior filing, the firm reported owning 21,085K shares , representing an increase of 0.64%. The firm decreased its portfolio allocation in NVO by 42.95% over the last quarter.
Fisher Asset Management holds 13,725K shares representing 0.31% ownership of the company. In its prior filing, the firm reported owning 14,130K shares , representing a decrease of 2.95%. The firm increased its portfolio allocation in NVO by 6.49% over the last quarter.
Bank Of America holds 13,054K shares representing 0.30% ownership of the company. In its prior filing, the firm reported owning 12,975K shares , representing an increase of 0.60%. The firm decreased its portfolio allocation in NVO by 70.26% over the last quarter.
Fayez Sarofim holds 11,816K shares representing 0.27% ownership of the company. In its prior filing, the firm reported owning 11,814K shares , representing an increase of 0.02%. The firm increased its portfolio allocation in NVO by 3.34% over the last quarter.
Renaissance Technologies holds 9,165K shares representing 0.21% ownership of the company. In its prior filing, the firm reported owning 10,786K shares , representing a decrease of 17.68%. The firm increased its portfolio allocation in NVO by 1.94% over the last quarter.
Novo Nordisk Background Information
(This description is provided by the company.)
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in nine countries, and affiliates or offices in five countries.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
